Copyright
©©The Author(s) 2022.
World J Stem Cells. Jan 26, 2022; 14(1): 76-91
Published online Jan 26, 2022. doi: 10.4252/wjsc.v14.i1.76
Published online Jan 26, 2022. doi: 10.4252/wjsc.v14.i1.76
GCSCs pathway | Involved pathway proteins | Therapeutic inhibitor or drug | Ref. |
Hedgehog (HH) | PTCH1, SMO, GLI | Vismodegib5E1RobotnikininGANT58GANT61HPI1-4GenisteinResveratrolCyclopamineMir-218SaridegibBMS-833923ErismodegibPF-0449913LY2940680 | [27,28,83,84] |
Notch/STAT3 | Notch ligands (DLL), Notch receptors, JAK, ERK, STAT3 | NapabucasinDemclzumab (anti-DLL4)TarextumabBBI-608 | [28,76,85,86] |
NANOG | NANOG, STAT3, Kinases | NapabucasinBBI-608BB1-503 | [28,73,75,85] |
Wnt/β-catenin | Wnt, β-catenin, LRP/FZD | Napabucasin BBI-608Vantictumab (anti-FZD)LGK974Foxy-5 | [28,77,78,85,86] |
- Citation: Hsieh HL, Yu MC, Cheng LC, Yeh TS, Tsai MM. Molecular mechanism of therapeutic approaches for human gastric cancer stem cells. World J Stem Cells 2022; 14(1): 76-91
- URL: https://www.wjgnet.com/1948-0210/full/v14/i1/76.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v14.i1.76